Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes

• Type: Article in International Scientific Journal
• Date: 2016

Authors

Pedrosa, AC (Author) Other; Reis Silva, A (Author) Other; Pinheiro Costa, J (Author) Other; Beato, J (Author) FMUP; Freitas da Costa, P (Author) Other; Manuel Falcão (Author) FMUP; Falcão-Reis F (Author) FMUP; Ângela Carneiro (Author) FMUP

Journal

Title: Clinical Ophthalmology

Vol. 10

Pages: 541-546

ISSN: 1177-5467

Publisher: Dove Medical Press

Indexing

ISI Web of Knowledge - 11 Citations

Scopus - 13 Citations

Other information

Authenticus ID: P-00K-BXE

DOI: 10.2147/opth.s90913

Abstract (EN): Purpose: To evaluate the 5-year results obtained in clinical practice in the treatment of neovascular age-related macular degeneration (nAMD) with anti-VEGF agents. Materials and methods: We retrospectively analyzed all patients with nAMD who initiated anti-VEGF treatment before October 2009. We collected data regarding visual and anatomical outcomes. Results: A total of 278 patients met the selection criteria. The mean number of intravitreal injections was 5.7 in the first year and 3.7 in the fifth year. A positive mean visual acuity variation of +3.7 Early Treatment Diabetic Retinopathy Study letters occurred in the first year, but no significant differences relative to baseline were observed thereafter. The majority of patients (71%) maintained stable visual acuity throughout follow-up. At 5 years, mean central macular thickness remained substantially inferior to baseline (-96.6 mu m), and 56% of patients maintained dry retinas. Conclusion: Anti-VEGF therapy leads to long-term visual stabilization in the great majority of patients.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 6